Furthermore, subsequent BM was more common in patients with adenocarcinoma histology (p = 0.001), EGFR-activating mutations (p < 0.001), and bone metastases at diagnosis, especially with spine involvement (p < 0.001). Here, EGFR is linked to adenocarcinoma.